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432from 2-dimensional transesopha-
geal echocardiography (TEE) (3).
However, the appropriateness of
this method for THV sizing has
recently been questioned (1,4,5).
Inappropriate THV size selection
is associated with paravalvular
regurgitation (PAR) (2,4), aortic
annular rupture (6), coronary
occlusion (7), and device emboli-
zation (8). These complications
strongly impact morbidity and
mortality after TAVR (7). Three-
dimensional assessments of the
aortic annulus by TEE (9,10) ormultidetector computed tomography (MDCT) have been
shown to predict PAR (2,4) because of better appreciation of
its complex 3-dimensional structure. Our group previously
found that MDCT annular area oversizing was the strongest
predictor for PAR (2) in a retrospective, multicenter analysis.
However, it is unknown whether this knowledge can be
translated into improved clinical outcomes when practically
applied by a readily available, reproducible MDCT annulus
area sizing algorithm (5).We therefore performed a prospec-
tive, multicenter, controlled trial to evaluate the impact of
integration of an MDCT annular area sizing algorithm on
TAVR outcomes (5).
Methods
Patients with high surgical risk or inoperable symptomatic
severe aortic stenosis, planed forTAVR in4 experienced centers
(St. Paul’sHospital,University ofBritishColumbia,Vancouver,
British Columbia, Canada; Quebec Heart and Lung Institute,
Laval University, Quebec City, Quebec, Canada; Aarhus
University Hospital Skejby, Aarhus, Denmark; and Vancouver
General Hospital, University of British Columbia, Vancouver,
British Columbia, Canada) were considered for this trial,
which was approved by the local ethical committees. Exclusion
criteria were an estimated glomerular ﬁltration rate of less than
35 ml/min (except for patients on chronic hemodialysis),
previous aortic valve replacement (“valve-in-valve”), andTAVR
with a THV other than the SAPIEN XT balloon-expandable
valve (Edwards Lifesciences, Irvine, California). Prospectively
enrolled, consecutive patients who underwent TAVR with the
implementation of the MDCT annular area sizing algorithm
(MDCT group) were compared with consecutive patients who
underwent TAVR without the algorithm (control group) prior
to trial initiation. For both groups, the availableTHVsizes were
20-, 23-, 26-, and 29-mm diameters. Each center contributed
equal numbers of patients to theMDCTgroup and the control
group. Because the trial was initiated in the beginning of 2012,
consecutive patients in the control group were treated in 2011
just before trial initiation. Sizing of the THV in the control
group was based on an integration of echocardiography
measurements and angiography (without standardizedmeasurements) but not on 3-dimensional MDCT area
assessment.
Study endpoints. The primary endpoint was the incidence
of more than mild PAR, and the secondary endpoint was the
composite of in-hospital death, aortic annular rupture (as a
marker of excessive oversizing), and severe PAR (as a marker
of excessive undersizing). Study endpoint analysis was per-
formed by intention to treat.
MDCT and THV size selection. All MDCT scans were
read by 1 experienced level 3 cardiac MDCT reader at
St. Paul’s Hospital (MDCT core laboratory) in concert and by
consensus with the local site. Examinations were performed
with either a 64-slice scanner (Discovery HD 750, GE
Healthcare, Waukesha, Wisconsin) or a second-generation
dual-source CT system (Siemens Somatom Deﬁnition Flash,
Siemens Healthcare, Erlangen, Germany). The protocol for
the single-source scanner included the injection of 80 to
120 ml of radio-contrast medium at 5 ml/s followed by
30 ml of normal saline (2). Electrocardiogram-gated dose
modulation was used, but heart rate reduction with beta-
blockade was not performed. Depending on patient size,
maximum tube current ranged between 450 and 700 mA
with a ﬁxed tube voltage of 100 kVp for patients with a body
mass index (BMI)<30 kg/m2 and 120 kVp for larger patients.
For the dual-source scanner, a contrast-enhanced MDCT
examination in the caudocranial direction with retrospective
gating was performed. Commercially available contrast
media (ioversol 350 mg/ml, Mallinckrodt Inc., Hazelwood,
Missouri) was used (20 ml for the test bolus and 70 ml for the
spiral scan). Contrast injection was followed by a 50-ml saline
ﬂush. Heart rate reduction with beta-blockade was not per-
formed. MDCT was performed with a 128  0.625 mm
collimation, z-ﬂying spot, gantry rotation time 280 ms, and
scan pitch 0.20 to 0.40 (depending on heart rate). Maximum
tube current ranged from 450 to 750 mA with ﬁxed tube
potential of 100 (BMI <30 kg/m2) or 120 kV (BMI >30
kg/m2). Electrocardiogram-controlled tube current modula-
tion was applied with reduction of the current to 20% and full
pulsing applied only from 30% to 70% of the RR interval.
MDCT annular area measurements were performed in
systole at 25% or 35% of the RR interval when the annulus is
the largest (5), depending on which of the 2 phase recon-
structions displayed better image quality. Recommendations
for THV size were based on anMDCT sizing algorithm with
an optimal goal of modest annulus area oversizing (nominal
THV area/MDCT annular area ¼ 5% to 10%) (Table 1) (5).
The algorithm ensures routine oversizing of the MDCT
aortic annular area (nominal THV area > MDCT annular
area), calculating a percentage of annular oversizing (nominal
THV area/MDCT annular area). Nominal external THV
areas for the 20-, 23-, 26-, and 29-mm SAPIEN XT THV
are 3.14 cm2, 4.15 cm2, 5.31 cm2, and 6.61 cm2, respectively.
Implantation with nominally ﬁlled deployment balloons
was performed by full injection of the indeﬂator volume.
When more than 20% area oversizing was anticipated
(or more than 15% oversizing in the presence of adverse aortic
Table 1
Multidetector Computed Tomography Annular Area
Sizing Algorithm
Annular Area, mm2
Percentage of Annular Area Oversizing, %
20-mm
THV
23-mm
THV
26-mm
THV
29-mm
THV
230 NR
240 NR (30.9)
250 25.7 UE
260 20.8 UE
270 16.4
280 12.2
290 8.3
300 4.7
310 1.3 NR
320 NR (1.9%) 29.8 UE
330 25.9 UE
340 22.2 UE
350 18.7
360 15.4
370 12.3
380 9.3
390 6.5
400 3.9 NR
410 1.3 NR (29.5)
420 NR (1.1) 26.4 UE
430 23.5 UE
440 20.7 UE
450 18.0
460 15.4
470 13.0
480 10.6
490 8.4
500 6.2
510 4.1 NR
520 2.1 NR (27.0)
530 0.2 24.6 UE
540 22.3 UE
550 20.1 UE
560 17.9
570 15.9
580 13.9
590 12.0
600 10.1
610 8.3
620 6.5
630 4.8
640 3.2
650 1.6
660 0.1
670 NR
The recommendation is to select a prosthesis with a cross-sectional area modestly larger than that
of the aortic annulus. A target of 5% to 10% area oversizing with upper and lower limits of 1% to
20% is suggested. The highlighted grey zones represent annular areas in which valve selection is
challenging. Selecting the larger valve will result in oversizing >20% and the smaller valve will
result in undersizing. Oversizing the annulus >20% may increase the risk of annular injury. Options
include underﬁlling the transcatheter heart value balloon or selecting a smaller valve size with an
attendant risk of paravalvular regurgitation.
NR ¼ not recommended; UE ¼ underexpansion.
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433root features), intentional underexpansion of the THV was
suggested. This was accomplished by reducing the volume of
ﬂuid within the valve deployment balloon by 10%. Adverseroot features included more than minimal left ventricular
outﬂow tract calciﬁcation and shallow sinuses of Valsalva.
Although 5% to 10% area oversizing was considered optimal,
most patients will not meet this target due to the large
increments between manufactured prosthesis sizes. We
therefore considered a range from 1% to 15% (20% in the
absence of adverse root features) as acceptable margins in the
sizing algorithm, with the integration of balloon underﬁlling
for those who would require oversizing in excess of 20%
by area.
In the MDCT group, TAVR operators were informed
about the MDCT area sizing recommendation before the
procedure. Operators were not obliged to follow the MDCT
area sizing recommendations but could choose the THV size
they considered most appropriate.
Echocardiography. Intraprocedural TEE was routinely per-
formed by level 3 echocardiographers highly experienced in
TAVR assessments. The aortic annulus was 2-dimensionally
imaged by periprocedural TEE in a 3-chamber view, and
a single diameter was documented. Echocardiographers were
blinded toward the MDCT measurements and the MDCT
sizing recommendation. Prior to discharge, transthoracic
echocardiography (TTE) was performed to assess PAR,
valve area, and transvalvular gradients. The grade of PAR was
rated as none, mild, moderate, or severe according to Valve
Academic Research Consortium criteria (11).
Statistical analysis. Analyses were performed using SPSS
statistics software (version 20.0, SPSS Inc., Chicago, Illi-
nois). Continuous variables are reported as mean  SD and
categorical variables by percentages. Continuous variables
were tested for a normal distribution (QQ plot) and
compared by the Student t test. For comparison of more
than 2 continuous parametric variables, an analysis of vari-
ance was used. Categorical variables were compared by the
Fisher exact test. All tests were 2-tailed, and a p value <0.05
was considered statistically signiﬁcant.
Results
Baseline characteristics. Of 266 patients in the trial, 133
consecutive patients underwent TAVR with the MDCT
sizing algorithm recommendation (MDCT group) and 133
consecutive patients without the algorithm (control group)
(University of British Columbia (2 sites): 166 patients; Laval
University: 56 patients; Aarhus University Hospital: 44
patients) (Fig. 1). Baseline characteristics are shown in
Table 2. Patients in the control group had a 1.2% higher
Society of Thoracic Surgeons score (p ¼ 0.007), which
reﬂects the broadening of TAVR indications to lower-risk
patients over the study period.
Valve selection and procedure. All patients received a
SAPIEN XT THV (Edwards Lifesciences) with valve sizes
of 20-, 23-, 26-, or 29-mm diameter available for both
groups. Prosthesis sizes and procedural characteristics are
shown in Table 3. Within the MDCT group, sizing
recommendations were followed in 80.5% of patients (107 of
133). In the 26 patients for which MDCT recommendations
Figure 1 Study Flowchart
MDCT ¼ multidetector computed tomography; SPH ¼ St. Paul’s Hospital; TAVR ¼ transcatheter aortic valve replacement; VHG ¼ Vancouver General Hospital.
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434were not followed, the implanted THV size was chosen
because of conﬂicting echocardiography recommendations
in 14 patients, balloon aortic valvuloplasty assessment in
2 patients, and operator preference (prosthesis size in
discordance with MDCT as well as echocardiography
recommendations) in 10 patients. In 9 patients, the MDCT
algorithm would have recommended a larger size and in 17
patients a smaller THV size. In this group (26 patients), there
were no cases of severe PAR, no annulus rupture, and no
in-hospital mortality. Compared with the control group,
the MDCT group was more often associated with the
use of an underﬁlled deployment balloon (13.5% vs. 0%;
p < 0.001) and implantation of the largest available (29-mm
diameter) prosthesis (27.1% vs. 16.5%; p ¼ 0.038). Whether
deployment balloons were nominally ﬁlled or underﬁlled did
not inﬂuence the rates of more than mild PAR (9.3% vs.
5.6%; p ¼ 0.595), aortic annulus rupture (0.8% vs. 0%;
p ¼ 0.702), THV embolization (0.8% vs. 0%; p ¼ 0.702), or
post-dilation (13.3% vs. 5.6%; p ¼ 0.342) (Fig. 2).
Post-implant echocardiography. Pre-discharge TTE doc-
umented comparable valve function in both MDCT and
control groups. Aortic valve area was 1.6  0.3 cm2 versus
1.6  0.4 cm2 (p ¼ 0.923) and mean gradient 10.0  3.8
mm Hg versus 9.9  4.6 mm Hg (p ¼ 0.96) in the MDCT
group versus control group, respectively. However, more than
mild PAR was less common in the MDCT group: 5.3% (7 of
133) versus 12.8% (17 of 133) (p ¼ 0.032). Similarly, severe
PAR was less common in the MDCT group: 0% versus 4.5%
(6 of 133) (p ¼ 0.013) (Fig. 3). The degree of annulus area
oversizing was signiﬁcantly associated with a reduction in
PAR. Annulus area oversizing was 16.4  12.1% in patients
with no PAR, 10.4  10.7% in patients with mild PAR, and
0.5 9.4% in patients with more thanmild PAR (p¼ 0.001).In as-treated analysis, more than mild PAR occurred nearly
twice as often in the control group (6 of 107 patients [5.6%] vs.
15 of 159 [9.4%]; p ¼ 0.111). There was no difference in
baseline aortic regurgitation grades between the MDCT
group and the control group (Table 2). The rates of more than
mild post-procedural PAR did not differ between patients
with or without more than mild pre-procedural aortic regur-
gitation (19 of 225 patients [8.4%] vs. 5 of 41 [12.2%]; p ¼
0.389). Of the patients with severe pre-procedural aortic
regurgitation, none had more than mild post-procedural
PAR.
Outcomes. Procedural outcomes are shown in Table 3.
There were 5 (3.8%) in-hospital deaths in the MDCT group
and 9 (6.8%) in the control group (p ¼ 0.272). The rates of
annular rupture were 0.8% versus 0.8% (p ¼ 1.0). The
combined secondary endpoint of in-hospital mortality, aortic
annular rupture, and severe PAR occurred in 3.8% (5 of 133)
in the MDCT group and 11.3% (15 of 133) in the control
group (p ¼ 0.02). In as-treated analysis, the secondary
endpoint occurred twice as often in the control group (5 of
107 patients [4.7%] vs. 15 of 159 [9.4%]; p ¼ 0.149), albeit
without statistical signiﬁcance. There was no signiﬁcant
difference in the occurrence of the primary endpoint
between the ﬁrst and second halves of the control group
(17.6% vs. 7.7%; p ¼ 0.119) or the ﬁrst and second halves of
the MDCT group (2.9% vs. 7.7%; p ¼ 0.267) (Table 4).
Discussion
In this prospective, multicenter, controlled trial, the inte-
gration of an MDCT annular area sizing algorithm reduced
the incidence of more than mild PAR and the composite
endpoint of in-hospital death, aortic annular rupture, and
Table 3
Annulus, Echocardiography Assessments, and
Procedural Characteristics
MDCT Group
(n ¼ 133)
Control Group
(n ¼ 133) p Value
Left ventricular ejection
fraction, %
53  14 51  15 0.175
Mean gradient, mm Hg 42  18 38  15 0.055
Aortic valve area, cm2 0.7  0.2 0.7  0.2 0.440
TEE annulus diameter, mm 22.9  2.2 22.5  3.0 0.224
MDCT short-axis diameter, mm 21.5  2.2 n/a n/a
MDCT long-axis diameter, mm 27.3  2.9 n/a n/a
MDCT mean diameter, mm 24.4  2.3 n/a n/a
MDCT annulus area, cm2 4.8  0.8 n/a n/a
Access type
Transfemoral 74 (99) 71 (95) 0.581
Transapical 18 (24) 28 (37) 0.058
Transaortic 8 (10) 1 (1) 0.006
Labeled prosthesis size
20 mm 0.8 (1) 1.5 (2) 0.561
23 mm 26.3 (35) 30.8 (41) 0.415
26 mm 45.9 (61) 51.1 (68) 0.390
29 mm 27.1 (36) 16.5 (22) 0.038
MDCT area oversizing, % 11.6  11.5 n/a n/a
Underﬁlled deployment balloon 13.5 (18) 0 < 0.001
Values are mean  SD or % (n).
n/a ¼ not applicable; TEE ¼ transesophageal echocardiography; other abbreviation as in Table 2.
Table 2 Patient Baseline Characteristics
MDCT Group
(n ¼ 133)
Control Group
(n ¼ 133) p Value
Age, yrs 82  8 81  8 0.207
Male 57 (76) 63 (84) 0.316
Height, cm 168  10 168  9 0.991
Weight, kg 77  18 75  18 0.464
BMI, kg/m2 27  6 27  6 0.414
Diabetes 32 (43) 35 (47) 0.604
Hypertension 84 (112) 79 (105) 0.268
Dyslipidemia 68 (90) 74 (99) 0.224
Smoking history 43 (58) 38 (50) 0.318
COPD 38 (50) 26 (35) 0.065
NYHA functional class 0.088
Class I 1 (1) 0
Class II 27 (36) 16 (21)
Class III 63 (84) 76 (101)
Class IV 9 (12) 8 (11)
Pre-procedural aortic
regurgitation
0.926
None 29.3 (39) 21.8 (29)
Mild 55.6 (74) 62.4 (83)
Moderate 13.5 (18) 14.3 (19)
Severe 1.5 (2) 1.5 (2)
Prior cerebrovascular accident 16 (21) 14 (19) 0.732
Prior open heart surgery 29 (39) 40 (53) 0.094
Porcelain aorta 11 (15) 10 (13) 0.689
Prior permanent pacemaker 12 (16) 13 (17) 0.852
Prior myocardial infarction 21 (28) 30 (40) 0.092
Hemodialysis 3 (4) 2 (3) 0.702
Pulmonary hypertension 40 (53) 29 (38) 0.039
Peripheral vascular disease 20 (26) 19 (25) 0.876
Atrial ﬁbrillation 38 (51) 39 (52) 0.900
STS PROM, % 5.8  3.2 7.0  3.5 0.007
GFR, ml/min 62  24 53  20 0.001
Values are mean  SD or % (n).
BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular
ﬁltration rate; MDCT ¼ multidetector computed tomography; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; STS PROM ¼ Society of Thoracic Surgeons Predicted
Risk of Mortality.
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435severe PAR, driven by the difference in severe PAR. The
strength of our study manifests in a clear, reproducible, and
readily available sizing algorithm, which was prospectively
implemented for THV sizing in 4 TAVR centers (3 in
Canada and 1 in Europe) and evaluated in a large cohort of
consecutive patients.
Although TAVR is an approved alternative to surgical
aortic valve replacement in selected patients (12,13), the
widening of its application to lower-risk patients may be
hampered by complications such as PAR and aortic root
injury. These TAVR complications can, to some extent, be
attributed to inappropriate THV size selection. Operators
performing TAVR have to rely on indirect measurements of
the aortic annulus for annular sizing and THV selection.
Since its inception, the traditional measurement of the aortic
annulus for TAVR was a single diameter from 2-dimensional
TEE imaging (3), but recently this method has been chal-
lenged by 3-dimensional annular assessments with MDCT(2,4,5,14). In comparison to sizing by direct surgical
inspection of the aortic annulus as a gold standard, some
studies have shown superiority of MDCT over echocardio-
graphic measurements (15,16). Our knowledge of the
complex 3-dimensional geometry of the consistently oval-
shaped annulus is expanding (1), and new sizing algorithms
that address the limitations of 2-dimensional imaging are
needed (5). A single-center retrospective study by Jilaihawi
et al. (4) compared the annulus area–derived diameter from
MDCT with the TEE diameter and found that MDCT
sizing reduced the incidence of PAR. Another study by
Hayashida et al. (17) implemented MDCT sizing prospec-
tively in 40 patients and found a lower rate of PAR compared
with that in a retrospective cohort of patients treated with
TEE sizing. They studied the cross-sectional maximum
diameter, area-derived diameter, and perimeter-derived
diameter. Although there was a small, prospective cohort in
their retrospective, single-center trial, this did not translate
into a clear and practical sizing algorithm. In contrast, in our
study, a clear and reproducible algorithm was applied
prospectively, which was found to be practical and useful by
TAVR operators across different centers for THV selection.
MDCT versus TEE. It was not the aim of this trial to
perform a head-to-head comparison of TEE sizing versus
MDCT sizing. Operators were not bound by recommenda-
tions from one or the other imaging modality but were able to
freely choose the THV size based on all available information,
including the MDCT area sizing recommendation, TEE
measurements, TTE evaluation, and aortic root angiograms.
For borderline cases, an aortic root angiogram during balloon
aortic valvuloplasty may also provide valuable insight for
Figure 2
Pre- and Post-TAVR MDCT in a Patient With Adverse Root Features and Intentional Underexpansion
of the Transcatheter Heart Valve
Because of adverse aortic root features (A, B) (large calcium nodule in the left ventricular outﬂow tract), the 26-mm transcatheter heart valve was intentionally underexpanded by
removing 10% of the nominal deployment balloon volume. With this strategy, there was more controlled annular stretch, and displacement of the calcium nodule toward the
ventricular septum was avoided (C), thereby reducing the risk of aortic annulus injury. Abbreviations as in Figure 1.
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436the aortic annular dimensions (18). Because there is no pro-
spective, randomized comparison of MDCT versus TEE
sizing reported in the literature, it is unknown whether THV
sizing by one of these imaging modalities may be superior.
We do not think that it is prudent to randomize patients
between imaging modalities nor to blind the operator to
any pre-procedural data because TAVR remains a complex
procedure with results that are supported by as much
pre-procedural data as possible. Importantly, though, our
data do conﬁrm the beneﬁt of integration of 3-dimensional
MDCT measurements on TAVR-related outcomes, em-
phasizing their importance in THV selection and solidifying
their role in TAVR.
Rationale for annulus area sizing. We elected to use
annular area for sizing because we have consistently found it
to be the most reproducible annular measurement (1,2,5)Figure 3
Pre- and Post-TAVR Imaging in an 80-Year-Old Male Patien
Integration of the MDCT Sizing Guideline Showing the Valu
(A) Double oblique transverse reformat of the basal ring/annulus on MDCT with a mean a
echocardiogram suggests an annular diameter of 21.0 mm. (C) A 23-mm balloon-expanda
signiﬁcant resultant paravalvular regurgitation. Abbreviations as in Figure 1.and the most predictive of greater than mild PAR (2).
Others have suggested that annular sizing should be per-
formed with perimeter measures of the annulus owing to its
lesser variability across the cardiac cycle (19). Importantly,
although perimeter may be less dynamic, there are growing
amounts of data to suggest that it does in fact change
through the cardiac cycle (20) and there remain signiﬁcant
limitations with these measurements owing to the lack of
appropriate tools on all MDCT image review workstations,
resulting in at times erroneous measurements and a lower
degree of reproducibility (5). Should these tools become
available on all workstations, the area oversizing guidelines
used for this trial could be replaced with a perimeter-based
sizing guideline but would require modiﬁcation because
annular perimeter oversizing does not translate to the same
percentage of area oversizing. As an example, 10% annulart With Severe Symptomatic Aortic Stenosis Enrolled Before
e of 3-Dimensional Imaging of the Aortic Annulus
nnular diameter of 25.3 mm and an area of 5.0 cm2. (B) The long-axis 2-dimensional
ble prosthesis was selected on the basis of the 2-dimensional echocardiogram with
Table 4 Procedural Outcomes
MDCT Group
(n ¼ 133)
Control Group
(n ¼ 133) p Value
Procedural mortality 0 (0) 0.8 (1) 0.316
In-hospital mortality 3.8 (5) 6.8 (9) 0.272
30-day mortality 5.3 (7) 6.8 (9) 0.606
Annular rupture 0.8 (1) 0.8 (1) 1.000
THV embolization 0 (0) 1.5 (2) 0.156
THV-in-THV implantation 0.8 (1) 2.3 (3) 0.314
Procedural myocardial infarction 0.8 (1) 0 (0) 0.316
Post-dilation 12.8 (17) 12.8 (17) 1.000
Permanent pacemaker
implantation
8.3 (11) 9 (12) 0.827
Paravalvular regurgitation
None 27.8 (37) 28.6 (38) 0.892
Mild 66.9 (89) 58.6 (78) 0.163
More than mild 5.3 (7) 12.8 (17) 0.032
Severe 0 (0) 4.5 (6) 0.013
Values are % (n).
THV ¼ transcatheter heart valve; other abbreviation as in Table 2.
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437area oversizing is mathematically equivalent to 5% perimeter
oversizing.
Intentional THV underexpansion. The sizes of most
currently available THVs differ by 3-mm increments. This is
more than the typical increments of surgical bioprosthesis
(2 mm). For borderline aortic annulus dimensions, THV size
selection may be challenging because excessive oversizing
increases the risk of aortic annulus rupture (6) and coronary
occlusion (7) and excessive undersizing increases the risk
for PAR (2) and valve embolization (8). In vitro studies and
post-implant MDCT in patients with intentionally under-
expanded balloon-expandable THVs (unpublished data)
have shown that current manufacturers’ recommended
deployment balloon ﬁll volumes routinely result in THV
inﬂow diameters very slightly below the stated nominal THV
diameter, and reducing the volume of ﬂuid within the
deployment balloon by 10% below the nominal volume
results in a reduction of the deployed inﬂow diameter to a
value intermediate between the fully expanded THV and the
next smaller THV (e.g., when a 26-mm balloon-expandable
THV is deployed, reducing the balloon volume by 10%
results in an inﬂow diameter between a 23- and 26-mm
THV). We therefore developed a strategy to manage
borderline cases by intentional underexpanding balloon-
expandable THVs, thereby minimizing the risks associated
with excessive oversizing. Our data showed that intentional
underexpansion in 18 selected patients led to comparable
hemodynamics and favorable clinical outcomes. However,
the durability of underexpanded THVs is unknown, and this
strategy may become less necessary as more THV sizes with
lower diameter increments become available.
Study limitations. Randomized trials render high levels of
evidence; however, choosing the appropriate THV size during
TAVR should be based on all available information and not
one single measurement. We therefore chose not to perform
a randomized comparison of different sizing modalities butrather study the impact of implementation of anMDCT area
sizing algorithm on overall outcomes. Therefore, 26 patients
received THV sizes not in accordance with MDCT recom-
mendations. Even if operators decided not to go with the
recommendations, size selection may still have been inﬂu-
enced by the proposed valve size. This non–pre-speciﬁed
subgroup is too small for valuable primary or secondary
endpoint comparisons. However, expert opinion appeared
effective in achieving procedural success in this subgroup.
The control group consisted of consecutive patients from
all 4 centers who underwent TAVR before the MDCT area
sizing recommendations were implemented. A learning
effect, which may have led to improved outcomes, could be
postulated. However, highly experienced operators, each
having performed more than 200 cases prior to the control
group, performed this trial in high-volume centers. We
therefore do not think that the differences were generated by
a learning curve.
Not all baseline characteristics were the same between
groups. The Society of Thoracic Surgeons score was lower in
the MDCT group, and the estimated glomerular ﬁltration
rate was lower in the control group. Although this dis-
crepancy was statistically signiﬁcant, the absolute difference
is clinically less relevant because it is not anticipated to
impact the primary endpoint of this trial.
Whereas all MDCT scans were read in a core laboratory,
the TTE and TEE were read locally at the participating site.
Grading of PAR may be heterogeneous across readers and
sites. However, all sites contributed equal numbers of patients
to both groups, which may counterbalance possible hetero-
geneity of echocardiography readings. Furthermore, all local
site reads were performed by level 3 echocardiographers with
signiﬁcant experience in TAVR and graded according to
standardized deﬁnitions (11).
All patients received a SAPIEN XT balloon-expandable
THV. Because self-expandable and balloon-expandable
THVs engage differently with the aortic annulus and leaf-
lets, our ﬁndings and algorithm may not be suitable for self-
expanding THVs. Furthermore, newer-generation devices
with paravalvular sealing systems (e.g., the SAPIEN 3
[Edwards Lifesciences] or the Sadra Medical Lotus [Boston
Scientiﬁc, Boston, Massachusetts]) may need less oversizing
or even tolerate prudent undersizing without an increased
risk of PAR (21).
Conclusions
In this prospective, multicenter, controlled trial the imple-
mentation of an MDCT annulus area sizing algorithm for
TAVR reduced PAR. Three-dimensional aortic annular
assessment and annular area sizing should be considered for
TAVR.
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